The medication also slows down stomach emptying, so patients are satisfied with smaller portions and feel less hungry overall
Monitor for: Gastrointestinal symptoms: Nausea or vomiting (occurring in approximately 1520% of patients at therapeutic doses per FDA labeling) Abdominal pain or cramping Diarrhea or constipation Loss of appetite or early satiety Bloating or abdominal distension Hypoglycemia indicators (particularly if you take other diabetes medications): Trembling, shakiness, or sweating Rapid heartbeat or palpitations Dizziness, lightheadedness, or confusion Hunger or irritability Headache or blurred vision Injection site reactions: Bruising, swelling, or hematoma formation Persistent pain or tenderness Redness or warmth suggesting inflammation Hardness or nodule formation under the skin Semaglutide's mechanism involves glucose-dependent insulin secretion, meaning hypoglycemia risk is generally low when used as monotherapy
A recent study investigating the degree of therapeutic inertia associated with the prescription of GLP-1 RAs in primary care in the UK found that 54.9% of people with diabetes had an HbA 1c level of 75 mmol/mol (9.0%) at first prescription of subcutaneous semaglutide, which is in keeping with baseline characteristics of our cohort [23]
Recalls & Warnings May 10, 2013 Protein Extract Recalled for Undeclared Allergens On May 6, 2013, Pure Herbs Ltd
After washing, the membranes were incubated for 1 h with horseradish peroxidase-labeled secondary antibodies
